Katherine Giannamore
    • Labeling & Claims
    • FDA Label Reviews
    • Label & Marketing Reviews
    • Ingredient Reviews
    • Supplement Facts Panels
    • Outer Packaging Requirements
    • Website Reviews
    • Nutrient Content Claims
    • Organic & Natural Claims
    • Structure/Function Claims
    • Disease Claims
    • Health Claims
    • Food, Supplements & Devices
    • FDA Food Services
    • Dietary Supplement Services
    • 30-Day Notification (NDI)
    • 510(k) / Premarket Clearance
    • Premarket Approval (PMA)
    • Imports, Enforcement & General Counsel
    • FDA Imports
    • Warning Letter Responses
    • FDA Consultant Services
  • About
  • Food & Drug Blog
  • Contact
(866) 785-0873 Schedule a Consultation

Tag: NDA

FDA Stops Company from Marketing Unapproved New Drugs

Disease Claims, Drugs, Enforcement, FDA, Injunction, Labeling, NDA, Warning LettersFDA

On January 30, 2015, and at the request of the U.S. Food and Drug Administration (FDA), a federal judge granted a consent decree of permanent injunction against Laclede, a U.S.-based manufacturer in connection with the marketing of unapproved new drugs. …

Read More

FDA Approval Required for Company Enjoined from Marketing Products

Disease Claims, Drug, Drugs, Enforcement, FDA, FDA Approval, Injunction, Labeling, Marshalls, NDA, SeizureFDA

On October 10, 2014, a federal judge from the U.S. District Court for the Southern District of Ohio sided with the U.S. Food & Drug Administration (“FDA”) and entered a consent decree for permanent injunction against Ascend Laboratories, LLC. As …

Read More

FDA Seizes Topical Creams Deemed Drugs

Disease Claims, Drug, Drugs, Enforcement, Labeling, NDAFDA

On May 16, 2014, the U.S. Food and Drug Administration (“FDA”), with assistance by the U.S. Attorney for the Southern District of Ohio, seized unapproved drugs valued at more than $11 million, which were marked by Ascend Laboratories of Montvale, …

Read More

Supreme Court to Review Design Defect Case against Generic Drug Company

ANDA, Drugs, Generic Drugs, NDA, Preemption, SCOTUSFDA

On March 19, 2013, the U.S. Supreme Court will hear arguments in Mutual Pharmaceutical Company, Inc. v. Karen L. Bartlett. The defendant-appellant in the case, Mutual Pharmaceutical Company (“Mutual”) appealed from a decision of the U.S. Court of Appeals for …

Read More

FDA Approves Bladder Control Drug for OTC Use, Highlighting Rx to OTC Switch

Drugs, NDA, OTC Drugs, Rx to OTC SwitchFDA

On January 25, 2013, the U.S. Food and Drug Administration (“FDA”) announced the approval of the first women’s bladder control product available without a doctor’s prescription. In the past, all bladder control drugs were only available by prescription. This product, …

Read More

FDA Approves Drug for Treatment of Plague Through Animal Efficacy Rule

Animal Efficacy, Drugs, FDA, Labeling, NDAFDA

On April 27, 2012, the U.S. Food and Drug Administration (“FDA”) approved Levaquin (levofloxacin), a drug used to treat those afflicted with plague. In addition to treating those with the deadly infection, Levaquin is also approved to reduce the risk …

Read More

FDA Approves Vivus Inc.’s Stendra to Treat Erectile Dysfunction

Drugs, Erectile Dysfunction, FDA, NDAFDA

On April 27, 2012, the U.S. Food and Drug Administration (“FDA”) approved the drug Stendra (avanafil), a drug used to treat erectile dysfunction (“ED”). Marketed by Vivus, Inc., Stendra is intended to be taken by men on an as-needed basis …

Read More

    Katherine L. Giannamore
    Rated by Super Lawyers


    loading ...
    Shehadeh Giannamore, PLLC

    Toll-free: (866) 785-0873
    Direct: (305) 507-9843
    Email: contact@giannamore-law.com

    Reachable seven days a week · Response within 24 hours

    Practice Areas

    • Food & Beverage
    • Dietary Supplements
    • Cosmetics & Labeling
    • Medical Devices
    • Drugs & OTC
    • Enforcement & Import Defense

    Popular Services

    • FDA Label Reviews
    • Ingredient Reviews
    • FDA Imports
    • Warning Letter Responses
    • 30-Day NDI Notification

    Firm

    • About
    • Food & Drug Blog
    • Contact
    • Google Reviews

    Information shared on this website and blog is for informational purposes only and may not provide the most up-to-date legal and regulatory information, as we do not provide updates to individual articles after publication. Any commentary or legal analysis herein is for general informational purposes and not to be relied upon for individual legal advice and does not establish an attorney-client relationship.

    © 2026 Shehadeh Giannamore, PLLC. All rights reserved.